GLAND - IntraDay Trade Analysis with Live Signals

Last Updated Time : 20 Dec 25, 07:02 am

IntraDay Trade Rating: 3.2

📊 Analysis: GLAND shows weak-to-moderate intraday potential. Current price (₹1,674) is below both the 50 DMA (₹1,799) and 200 DMA (₹1,803), reflecting short-term weakness. RSI at 31.9 indicates oversold territory, which could trigger a technical bounce, but MACD (-48.4) confirms strong bearish momentum. Volume (70.6k) is above the weekly average (41k), showing active participation, though sentiment remains cautious.

💡 Optimal Buy Price: ₹1,665–₹1,675 (near support zone).

🎯 Profit Exit Levels: ₹1,695 (first resistance), ₹1,715 (second resistance).

🛡️ Stop-Loss: ₹1,650 (below intraday support).

⏱️ If Already Holding: Exit intraday if price fails to sustain above ₹1,674 or if MACD continues bearish. Consider booking profits near ₹1,695–₹1,715 if momentum improves during the session.

Positive

• 📈 ROCE (15.8%) and ROE (11.6%) highlight efficient capital use.
• 💰 Debt-free balance sheet ensures financial stability.
• 📊 Quarterly PAT growth from ₹269 Cr. to ₹302 Cr. (7.2% variation).
• 🌍 FII holding increased (+0.51%), showing foreign investor confidence.

Limitation

• ⚠️ MACD negative (-48.4) indicates strong bearish momentum.
• 📉 RSI (31.9) shows oversold conditions, risk of further downside before recovery.
• 📊 Current price below DMA levels reflects short-term weakness.
• 📉 DII holding decreased (-0.23%), showing domestic investor caution.
• 📊 PEG ratio (-6.94) highlights unsustainable growth prospects.

Company Negative News

• 📰 No major negative news reported, but technical weakness and valuation concerns weigh on sentiment.

Company Positive News

• 📰 Quarterly profit growth supports positive sentiment despite technical weakness.
• 🌍 FII inflows add confidence to fundamentals.

Industry

• 🏭 Pharma sector trading at PE 30.6, slightly higher than GLAND’s valuation (23.8).
• 📈 Industry demand supported by healthcare expansion and global pharma exports.

Conclusion

⚖️ GLAND is fundamentally stable with debt-free status and profit growth, but intraday signals are weak due to bearish MACD and oversold RSI. Cautious entry near ₹1,665–₹1,675 with profit exits at ₹1,695–₹1,715 is possible, while maintaining a strict stop-loss at ₹1,650.

Would you like me to extend this into a peer benchmarking overlay comparing GLAND with other pharma sector stocks, or should we focus on basket rotation signals for intraday workflow optimization?